Reduced effectiveness: If your typical dose seems less effective than previous weeks from the same vial, potency may have decreased
To maintain your progress: Adopt a balanced, nutrient-rich diet: Focus on whole foods such as fruits, vegetables, lean proteins, and whole grains
Real-world data show that the GLP-1 receptor agonists semaglutide and tirzepatide not only manage blood sugar and weight but also mirror their heart-protective effects from clinical trials in everyday patients
Key highlights: Semaglutide (Novo Nordisk) gaining traction against Tirzepatide (Eli Lilly) Semaglutides market share increased to 21% from 13% in just two months Tirzepatide still holds around 79% share of the GLP-1 segment Indias anti-obesity drug market has tripled to over 1,500 crore in the past year Lower pricing, wider physician adoption, and improved availability are helping Novo Nordisk expand its footprint
Diabetes Care 2010;33(7):16581664
Clinical trials showed continued weight loss through 72 weeks, with the bulk of results occurring in the first 40 weeks
